Cancer

Showing 15 posts of 1067 posts found.

Novartis image

Novartis secures first US biosimilar product

March 6, 2015
Research and Development, Sales and Marketing Amgen, Cancer, FDA, Neupogen, Novartis, Sandoz, Zarxio, biosimilar, filgrastim-sndz

Novartis’ generic arm Sandoz has won the race to become the first company to market a biosimilar in the US …

Keytruda image

Merck and Eisai partner on cancer therapy trial

March 6, 2015
Research and Development, Sales and Marketing Bayer, Cancer, FDA, Halaven, Lenvima, Merck, Stivarga, keytruda, oncology, pd1

Merck and Eisai are teaming up for collaborative trials to test the effects of using combinations of each company’s oncology …

Cancer image

Precision medicine: the future of cancer treatment?

March 2, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, Cancer, Celgene, Precision, melanoma, oncology, underwood

There are plenty of advances in oncology treatments to be excited about – from immunotherapy to cancer vaccines and monoclonal …

Eisai image

Eisai cancer drug performs in sarcoma disease

February 26, 2015
Sales and Marketing Cancer, Eisai, Halaven, eribulin, sarcoma, tumour

Eisai’s cancer drug Halaven met its primary endpoint and demonstrated overall survival benefit in two distinct solid tumour types in …

FDA in Novartis cancer drug U-turn

February 24, 2015
Research and Development, Sales and Marketing Cancer, FDA, Farydak, Novartis, Revlimid, Velcade, myeloma

The FDA has overturned an earlier advisory committee recommendation and decided to approve Novartis’ blood cancer drug Farydak. In November …

Pills image

Hormone replacement therapy elevates ovarian cancer risk

February 13, 2015
Research and Development, Sales and Marketing Cancer, HRT, Lancet, Oxford, oncology, ovarian

According to a new study women who undergo hormone replacement therapy nearly double their risk of developing ovarian cancer.  Findings …

cancer image

Half of UK population will get cancer

February 4, 2015
Research and Development, Sales and Marketing CDF, CRUK, Cancer, Jevtana, Sanofi, cabazitaxel

New figures from Cancer Research UK (CRUK) suggest that one in two people will develop cancer at some point in …

FDA fast-tracks Roche lung cancer drug

February 2, 2015
Sales and Marketing Cancer, FDA, MPDL3280A, Roche, bladder, lung, oncology, pdl1

Roche will be celebrating after its investigational cancer drug MPDL3280A has been fast-tracked by the FDA for the second time. …

Novartis image

Novartis earns EMA and FDA nods for Jakavi and Bexsero

January 26, 2015
Sales and Marketing Bexsero, Cancer, EU, FDA, Jakavi, Novartis, US, meningitis, ruxolitinib

Novartis has secured the regulatory go-ahead for two of its drugs, after the EMA recommended Jakavi for a rare blood …

T cell image

UK makes £30m investment in T-Cell cancer therapy

January 22, 2015
Research and Development, Sales and Marketing Autolus, Cancer, London, T cell, UK, government, oncology, syncona

The UK is making a £30 million R&D investment into a promising new type of cancer treatment and is to …

Lilly image

Lilly, BMS and Merck unite for cancer trials

January 13, 2015
Research and Development, Sales and Marketing BMS, Cancer, Galunisertib, Merck, NSCLC, keytruda, lilly, oncology, opdivo

Lilly will test some of its compounds in combination with rival cancer drugs from Bristol-Myers Squibb and Merck, the companies …

dendreon image

Another NICE no for Dendreon cancer drug

January 13, 2015
Sales and Marketing Cancer, Dendreon, FDA, NHS, NICE, Provenge, sipuleucel-T

Dendreon has seen its prostate cancer treatment for people whose disease has spread and who are not yet suitable for …

NHS drops 25 treatments from Cancer Drugs Fund

January 12, 2015
Sales and Marketing Afinitor, CDF, Cancer, Cancer Drugs Fund, Eisa, Halaven, Heribulin, Jevtana, NHS, Sanofi, Zaltrap, aflibercept, cabazitaxel, everolimus

Twenty-five cancer treatments will be removed from the Cancer Drugs Fund list, NHS England has announced. Having concluded its review …

AZ image

AstraZeneca drops CDF application

January 12, 2015
Sales and Marketing AstraZeneca, CDF, Cancer, NHS, NICE, lynparza, olaparib

AstraZeneca has withdrawn its application for its drug Lynparza to be on the Cancer Drugs Fund (CDF), citing concerns with …

The Gateway to Local Adoption Series

Latest content